Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05386069 · ClinicalTrials.gov registry record · Phase 3

Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use

A Phase 3 study, sponsored by Prisma Health-Upstate.

Completed
Registry status
Phase 3
Development phase
10
Enrollment target

NCT05386069 is a Phase 3 study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05386069, a Phase 3 study, has completed, sponsored by Prisma Health-Upstate.

COMPLETED
Registry status
Phase 3
Development phase
10 participants
Enrollment target

Study Summary

The objective of this study is to evaluate narcotic use after implementation of a Non-Opioid Multimodal Pain (NOMO) protocol in patients who are undergoing a urogynecologic procedure. The study will also evaluate secondary outcomes, including: post-operative pain rating, length of hospital stay, postoperative antiemetic use, bladder catheterization at discharge, number of post-operative phone calls, and rate of reported side effects of opioid use (nausea/constipation). Study participants will be asked to utilize the validated Brief Pain Inventory (appendix A) scale to assess post-operative pain levels. Based on inpatient post-operative opioid use and number of opioid pills prescribed at discharge, an attempt will be made to develop an algorithm for recommended opioid prescribing patterns.

Interventions

  • DRUG NOMO Protocol

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-11-15
Est. Completion 2021-06-01
Phase Phase 3

Sponsor

Prisma Health-Upstate

67 total trials

What the Registry Record Tells You About NCT05386069

The ClinicalTrials.gov registry entry for NCT05386069 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which NOMO Protocol is the first listed.

NCT05386069 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05386069 about?

NCT05386069 is a clinical study titled "Does a Non-Opioid Multimodal Pain (NOMO) Protocol Decrease Narcotic Use". The objective of this study is to evaluate narcotic use after implementation of a Non-Opioid Multimodal Pain (NOMO) protocol in patients who are undergoing a urogynecologic procedure. The study will also evaluate secondary outcomes, including: post-operative pain rating, length of hospital stay, pos...

What is the current status of trial NCT05386069?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2019-11-15. Estimated completion is 2021-06-01.

What interventions are being tested in trial NCT05386069?

The interventions under investigation include: NOMO Protocol (DRUG).

Who is sponsoring clinical trial NCT05386069?

This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.